Page 1445 - Hematology_ Basic Principles and Practice ( PDFDrive )

1287.e4 Part VII Hematologic Malignancies

128. Lee JL, Kim MK, Lee KH, et al: Extranodal marginal zone B-cell mucosa-associated lymphoid tissue type treated with cladribine: 6 year
lymphomas of mucosa-associated lymphoid tissue-type of the orbit and follow-up of a phase II trial. Ann Oncol 17:1722, 2006.
ocular adnexa. Ann Hematol 84:13, 2005. 149. Jager G, Hofler G, Linkesch W, et al: Occurrence of a myelodysplastic
129. Suh CO, Shim SJ, Lee SW, et al: Orbital marginal zone B-cell lym- syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA)
phoma of MALT: radiotherapy results and clinical behavior. Int J Radiat treatment of a low-grade gastrointestinal MALT lymphoma. Case
Oncol Biol Phys 65:228, 2006. report and review of the literature. Haematologica 89:ECR01, 2004.
130. Tanimoto K, Kaneko A, Suzuki S, et al: Primary ocular adnexal MALT 150. Salar A, Domingo-Domenech E, Estany C, et al: Combination therapy
lymphoma: a long-term follow-up study of 114 patients. Jpn J Clin with rituximab and intravenous or oral fludarabine in the first-line,
Oncol 37:337, 2007. systemic treatment of patients with extranodal marginal zone B-cell
131. Tsang RW, Gospodarowicz MK, Pintilie M, et al: Localized mucosa- lymphoma of the mucosa-associated lymphoid tissue type. Cancer
associated lymphoid tissue lymphoma treated with radiation therapy 115:5210, 2009.
has excellent clinical outcome. J Clin Oncol 21:4157, 2003. 151. Raderer M, Wohrer S, Bartsch R, et al: Phase II study of oxaliplatin
132. Uno T, Isobe K, Shikama N, et al: Radiotherapy for extranodal, for treatment of patients with mucosa-associated lymphoid tissue
marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23:8442, 2005.
originating in the ocular adnexa: a multiinstitutional, retrospective 152. Kahl BS, Bartlett NL, Leonard JP, et al: Bendamustine is effective
review of 50 patients. Cancer 98:865, 2003. therapy in patients with rituximab-refractory, indolent B-cell non-
133. Goda JS, Gospodarowicz M, Pintilie M, et al: Long-term outcome Hodgkin lymphoma: results from a Multicenter Study. Cancer 116:106,
in localized extranodal mucosa-associated lymphoid tissue lymphomas 2010.
treated with radiotherapy. Cancer 116:3815, 2010. 153. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus ritux-
134. Stafford SL, Kozelsky TF, Garrity JA, et al: Orbital lymphoma: radio- imab is effective and has a favorable toxicity profile in the treatment
therapy outcome and complications. Radiother Oncol 59:139, 2001. of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol
135. Husain A, Roberts D, Pro B, et al: Meta-analyses of the association 23:3383, 2005.
between Chlamydia psittaci and ocular adnexal lymphoma and the 154. Kiesewetter B, Mayerhoefer ME, Lukas J, et al: Rituximab plus benda-
response of ocular adnexal lymphoma to antibiotics. Cancer 110:809, mustine is active in pretreated patients with extragastric marginal zone
2007. B cell lymphoma of the mucosa-associated lymphoid tissue (MALT
136. Akbulut H, Soykan I, Yakaryilmaz F, et al: Five-year results of the treat- lymphoma). Ann Hematol 93:249, 2014.
ment of 23 patients with immunoproliferative small intestinal disease: 155. O’Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experi-
a Turkish experience. Cancer 80:8, 1997. ence with the novel proteasome inhibitor bortezomib in patients with
137. Al-Bahrani ZR, Al-Mondhiry H, Bakir F, et al: Clinical and pathologic indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin
subtypes of primary intestinal lymphoma. Experience with 132 patients Oncol 23:676, 2005.
over a 14-year period. Cancer 52:1666, 1983. 156. Kirschbaum M, Frankel P, Popplewell L, et al: Phase II study of vori-
138. Ben-Ayed F, Halphen M, Najjar T, et al: Treatment of alpha chain nostat for treatment of relapsed or refractory indolent non-Hodgkin’s
disease. Results of a prospective study in 21 Tunisian patients by the lymphoma and mantle cell lymphoma. J Clin Oncol 29:1198,
Tunisian-French intestinal Lymphoma Study Group. Cancer 63:1251, 2011.
1989. 157. Koch P, del Valle F, Berdel WE, et al: Primary gastrointestinal non-
139. Fischbach W, Tacke W, Greiner A, et al: Regression of immunoprolif- Hodgkin’s lymphoma: II. Combined surgical and conservative or
erative small intestinal disease after eradication of Helicobacter pylori. conservative management only in localized gastric lymphoma–results
Lancet 349:31, 1997. of the prospective German Multicenter Study GIT NHL 01/92. J Clin
140. Bertoni F, Zucca E: State-of-the-art therapeutics: marginal-zone lym- Oncol 19:3874, 2001.
phoma. J Clin Oncol 23:6415, 2005. 158. Zinzani PL, Stefoni V, Musuraca G, et al: Fludarabine-containing
141. Conconi A, Martinelli G, Thieblemont C, et al: Clinical activity of chemotherapy as frontline treatment of nongastrointestinal mucosa-
rituximab in extranodal marginal zone B-cell lymphoma of MALT type. associated lymphoid tissue lymphoma. Cancer 100:2190, 2004.
Blood 102:2741, 2003. 159. Aviles A, Nambo MJ, Neri N, et al: Mucosa-associated lymphoid tissue
142. Martinelli G, Laszlo D, Ferreri AJ, et al: Clinical activity of rituximab (MALT) lymphoma of the stomach: results of a controlled clinical trial.
in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not Med Oncol 22:57, 2005.
eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23:1979, 160. Wohrer S, Raderer M, Kaufmann H, et al: Effective treatment of
2005. indolent non-hodgkin’s lymphomas with mitoxantrone, chlorambucil
143. Hammel P, Haioun C, Chaumette MT, et al: Efficacy of single-agent and prednisone. Onkologie 28:73, 2005.
chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue 161. Raderer M, Wohrer S, Streubel B, et al: Activity of rituximab plus cyclo-
lymphoma with prominent gastric expression. J Clin Oncol 13:2524, phosphamide, doxorubicin/mitoxantrone, vincristine and prednisone
1995. in patients with relapsed MALT lymphoma. Oncology 70:411, 2006.
144. Levy M, Copie-Bergman C, Gameiro C, et al: Prognostic value of trans- 162. Rambaud JC, Halphen M, Galian A, et al: Immunoproliferative small
location t(11;18) in tumoral response of low-grade gastric lymphoma intestinal disease (IPSID): relationships with alpha-chain disease and
of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin “Mediterranean” lymphomas. Springer Semin Immunopathol 12:239,
Oncol 23:5061, 2005. 1990.
145. Levy M, Copie-Bergman C, Molinier-Frenkel V, et al: Treatment of 163. Esmaeli B, McLaughlin P, Pro B, et al: Prospective trial of targeted
t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for
with rituximab and chlorambucil: clinical, histological, and molecular front-line treatment of early-stage extranodal indolent ocular adnexal
follow-up. Leuk Lymphoma 51:284, 2010. lymphoma. Ann Oncol 20:709, 2009.
146. Zucca E, Conconi A, Laszlo D, et al: Addition of rituximab to chloram- 164. Hoffmann M, Troch M, Eidherr H, et al: 90Y-ibritumomab tiuxetan
bucil produces superior event-free survival in the treatment of patients (Zevalin) in heavily pretreated patients with mucosa associated lym-
with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the phoid tissue lymphoma. Leuk Lymphoma 52:42, 2011.
IELSG-19 Randomized Study. J Clin Oncol 31:565, 2013. 165. Leahy MF, Turner JH: Radioimmunotherapy of relapsed indolent non-
147. Zucca E, Conconi A, Martinelli G, et al: Chlorambucil plus rituximab Hodgkin lymphoma with 131I-rituximab in routine clinical practice:
produces better event-free and progression-free survival in comparison 10-year single-institution experience of 142 consecutive patients. Blood
with chlorambucil or rituximab alone in extranodal marginal zone 117:45, 2011.
B-cell lymphoma (MALT lymphoma): final results of the IELSG-19 166. Witzens-Harig M, Hensel M, Unterhalt M, et al: Treatment of limited
study. Hematol Oncol 31(Suppl 1):97, 2013. stage follicular lymphoma with Rituximab immunotherapy and involved
148. Jager G, Neumeister P, Quehenberger F, et al: Prolonged clinical remis- field radiotherapy in a prospective multicenter Phase II trial-MIR trial.
sion in patients with extranodal marginal zone B-cell lymphoma of the BMC Cancer 11:87, 2011.